These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23431367)

  • 1. Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan-hydrochlorothiazide association in a model of very advanced nephropathy.
    Arias SC; Valente CP; Machado FG; Fanelli C; Origassa CS; de Brito T; Camara NO; Malheiros DM; Zatz R; Fujihara CK
    PLoS One; 2013; 8(2):e56215. PubMed ID: 23431367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An association of losartan-hydrochlorothiazide, but not losartan-furosemide, completely arrests progressive injury in the remnant kidney.
    Arias SC; Souza RA; Malheiros DM; Fanelli C; Fujihara CK; Zatz R
    Am J Physiol Renal Physiol; 2016 Jan; 310(2):F135-43. PubMed ID: 26538442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Losartan-hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model.
    Fujihara CK; Malheiros DM; Zatz R
    Am J Physiol Renal Physiol; 2007 Jun; 292(6):F1810-8. PubMed ID: 17344184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
    Fujihara CK; Kowala MC; Breyer MD; Sena CR; Rodrigues MV; Arias SCA; Fanelli C; Malheiros DM; Jadhav PK; Montrose-Rafizadeh C; Krieger JE; Zatz R
    Sci Rep; 2017 Aug; 7(1):7899. PubMed ID: 28801620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
    Gonçalves AR; Fujihara CK; Mattar AL; Malheiros DM; Noronha Ide L; de Nucci G; Zatz R
    Am J Physiol Renal Physiol; 2004 May; 286(5):F945-54. PubMed ID: 15075190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An extremely high dose of losartan affords superior renoprotection in the remnant model.
    Fujihara CK; Velho M; Malheiros DM; Zatz R
    Kidney Int; 2005 May; 67(5):1913-24. PubMed ID: 15840039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney.
    Fujihara CK; DE Lourdes Noronha I; Malheiros DMAC; Antunes GR; DE Oliveira IB; Zatz R
    J Am Soc Nephrol; 2000 Feb; 11(2):283-290. PubMed ID: 10665935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model.
    Fujihara CK; Vieira JM; Sena CR; Ventura BH; Malheiros DM; Zatz R
    Am J Nephrol; 2010; 32(2):95-102. PubMed ID: 20551627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of losartan, in monotherapy or in association with hydrochlorothiazide, in chronic nephropathy resulting from losartan treatment during lactation.
    Fanelli C; Fernandes BH; Machado FG; Okabe C; Malheiros DM; Fujihara CK; Zatz R
    Am J Physiol Renal Physiol; 2011 Sep; 301(3):F580-7. PubMed ID: 21653629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Kujal P; Chábová VČ; Vernerová Z; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Vaňourková Z; Husková Z; Opočenský M; Skaroupková P; Schejbalová S; Kramer HJ; Rakušan D; Malý J; Netuka I; Vaněčková I; Kopkan L; Cervenka L
    Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1159-69. PubMed ID: 20880190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Abe M; Maruyama N; Suzuki H; Inoshita A; Yoshida Y; Okada K; Soma M
    Heart Vessels; 2013 Jul; 28(4):480-9. PubMed ID: 22914905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system blockade alone or combined with ET
    Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
    Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of strict blood pressure lowering by losartan/hydrochlorothiazide combination therapy and high-dose amlodipine monotherapy on microalbuminuria: the ALPHABET study.
    Fukutomi M; Hoshide S; Eguchi K; Watanabe T; Shimada K; Kario K
    J Am Soc Hypertens; 2012; 6(1):73-82. PubMed ID: 22054782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NLRP3 inflammasome inhibition ameliorates tubulointerstitial injury in the remnant kidney model.
    Foresto-Neto O; Ávila VF; Arias SCA; Zambom FFF; Rempel LCT; Faustino VD; Machado FG; Malheiros DMAC; Abensur H; Camara NOS; Zatz R; Fujihara CK
    Lab Invest; 2018 Jun; 98(6):773-782. PubMed ID: 29511302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Single and Combined Losartan and Tempol Treatments on Oxidative Stress, Kidney Structure and Function in Spontaneously Hypertensive Rats with Early Course of Proteinuric Nephropathy.
    Karanovic D; Grujic-Milanovic J; Miloradovic Z; Ivanov M; Jovovic D; Vajic UJ; Zivotic M; Markovic-Lipkovski J; Mihailovic-Stanojevic N
    PLoS One; 2016; 11(8):e0161706. PubMed ID: 27560781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
    Čertíková Chábová V; Kujal P; Škaroupková P; Varňourková Z; Vacková Š; Husková Z; Kikerlová S; Sadowski J; Kompanowska-Jezierska E; Baranowska I; Hwang SH; Hammock BD; Imig JD; Tesař V; Červenka L
    Kidney Blood Press Res; 2018; 43(2):329-349. PubMed ID: 29529602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease.
    Borges CM; Fujihara CK; Malheiros DMAC; de Ávila VF; Formigari GP; Lopes de Faria JB
    Am J Physiol Renal Physiol; 2020 May; 318(5):F1229-F1236. PubMed ID: 32249610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.
    Ismail B; deKemp RA; Croteau E; Hadizad T; Burns KD; Beanlands RS; DaSilva JN
    PLoS One; 2017; 12(5):e0177451. PubMed ID: 28542215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy.
    Fujihara CK; De Nucci G; Zatz R
    J Am Soc Nephrol; 1995 Jan; 5(7):1498-507. PubMed ID: 7535572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease.
    Dilauro M; Zimpelmann J; Robertson SJ; Genest D; Burns KD
    Am J Physiol Renal Physiol; 2010 Jun; 298(6):F1523-32. PubMed ID: 20357030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.